<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552002</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-2019-03-227</org_study_id>
    <nct_id>NCT04552002</nct_id>
  </id_info>
  <brief_title>The Effect of Synbiotic Consumption on Glycemic, Inflammatory Markers and Body Composition on Prediabetic and Diabetic Patients</brief_title>
  <official_title>The Effect of Synbiotic Consumption on Glycemic, Inflammatory Markers and Body Composition on Prediabetic and Diabetic Patients: A Double Blinded Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imam Abdulrahman Bin Faisal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imam Abdulrahman Bin Faisal University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial that will be conducted on Saudi prediabetic and&#xD;
      diabetic adults aged 18 to 70 years. The aim of the study is to investigate the effect of&#xD;
      synbiotic consumption on gut microbiome, glycemic control, and other diabetes-related&#xD;
      outcomes in patients with prediabetes and diabetes. A total of 160 participants will be&#xD;
      recruited from King Fahd Hospital of the University, Eastern Province, Saudi Arabia and&#xD;
      randomly assigned to synbiotic group (prediabetic and diabetic, n=40 each group) or control&#xD;
      group (prediabetic and diabetic, n=40 each group) for a 6-month trial. A structured&#xD;
      questionnaire will be used for data collection from subjects. The questionnaire will include&#xD;
      data related to socioeconomic status, health and diet related history. Primary outcomes&#xD;
      including gut microbiome sequencing, glycemic control related parameters and secondary&#xD;
      outcomes including inflammatory markers, food intolerance and anthropometric measurements&#xD;
      will be measured before the study, after 3 months and after 6 months. The findings of the&#xD;
      current study will shed light on the significance of synbiotic consumption on glycemic&#xD;
      control and other diabetes-related outcomes and their relation to food allergy and&#xD;
      autoimmunity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic markers</measure>
    <time_frame>6 months</time_frame>
    <description>HbA1c, FBG (through blood samples)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>6 months</time_frame>
    <description>IL-1, IL-10, CRP, IFN-γ (through blood samples)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Composition parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Muscle mass, Fat mass (through a body composition analyzer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>6 months</time_frame>
    <description>Height and weight will be measured to obtain BMI (kg/m2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>6 months</time_frame>
    <description>in (cm) by a measurement tape</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome sequencing</measure>
    <time_frame>6 months</time_frame>
    <description>Will be obtained through stool samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Dietary Supplements</condition>
  <arm_group>
    <arm_group_label>Synbiotic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group:&#xD;
Will receive synbiotic supplements: one capsule/day. Each capsule contains 20 billion CFU multi-strain probiotics + prebiotics (inulin and oligosaccharides) for a duration of 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will receive a placebo. The placebo will be similar to the synbiotic supplements in appearance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Synbiotic group</intervention_name>
    <description>Probiotics and prebiotics</description>
    <arm_group_label>Synbiotic group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with type 1 diabetes&#xD;
&#xD;
          -  Patients on insulin therapy&#xD;
&#xD;
          -  Patients on antibiotics&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Smoking individuals&#xD;
&#xD;
          -  Patients with comorbidities (except for hyperlipidemia and blood pressure)&#xD;
&#xD;
          -  Patients taking immunosuppressants&#xD;
&#xD;
          -  Patients taking probiotics, prebiotics or synbiotics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with prediabetes (HbA1c of 5.7- 6.4% or a fasting plasma glucose of 100 -125&#xD;
             mg/dl)&#xD;
&#xD;
          -  Patients with type 2 diabetes (HbA1c of ≥ 6.5% or a fasting plasma glucose of ≥ 126&#xD;
             mg/dl&#xD;
&#xD;
          -  Male and female patients aged (18-70) years&#xD;
&#xD;
          -  Patients with HbA1c of ≥ 5.7 or a fasting plasma glucose of ≥100 mg/dl&#xD;
&#xD;
          -  BMI ≥ 25&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Razan A Algarni, Bachelor</last_name>
    <phone>0569444331</phone>
    <email>raaalgarni@iau.edu.sa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tunny Sebastian, PhD</last_name>
    <phone>0556391380</phone>
    <email>tspurayidathil@iau.edu.sa</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Imam Abdulrahman Bin Faisal University</investigator_affiliation>
    <investigator_full_name>Razan Algarni</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

